OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review
Wei Zhang, Luo Chu, Zun-Yi Zhang, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 8
Wei Zhang, Luo Chu, Zun-Yi Zhang, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 8
Showing 8 citing articles:
Unveiling the promise of PD1/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma
Fei Chen, Jian Sheng, Xiaoping Li, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116659-116659
Open Access | Times Cited: 4
Fei Chen, Jian Sheng, Xiaoping Li, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116659-116659
Open Access | Times Cited: 4
Histopathologic Grading of Residual Tumor Predicts Survival of Intrahepatic Cholangiocarcinoma Patients Treated With Neoadjuvant Therapy
Gaohua Wu, Xiufen Chen, Rongkui Luo, et al.
The American Journal of Surgical Pathology (2025)
Closed Access
Gaohua Wu, Xiufen Chen, Rongkui Luo, et al.
The American Journal of Surgical Pathology (2025)
Closed Access
Conversion therapy combined with ALPPS for the treatment of intrahepatic cholangiocarcinoma: a case report
Hengyu Tian, Qinghua He, Chidan Wan
Frontiers in Oncology (2025) Vol. 15
Open Access
Hengyu Tian, Qinghua He, Chidan Wan
Frontiers in Oncology (2025) Vol. 15
Open Access
Case report: Translational treatment of unresectable intrahepatic cholangiocarcinoma: Tislelizumab, Lenvatinib, and GEMOX in one case
Hewei Zhang, Haibo Yu
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
Hewei Zhang, Haibo Yu
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
Tumor budding in pre-neoadjuvant biopsy and post-neoadjuvant resection specimens is associated with poor prognosis in intrahepatic cholangiocarcinoma—a cohort study of 147 cases by modified ITBCC criteria
Gaohua Wu, Rongkui Luo, Qianhui Xu, et al.
Virchows Archiv (2024) Vol. 485, Iss. 5, pp. 913-923
Open Access | Times Cited: 1
Gaohua Wu, Rongkui Luo, Qianhui Xu, et al.
Virchows Archiv (2024) Vol. 485, Iss. 5, pp. 913-923
Open Access | Times Cited: 1
PD-L1 inhibitor plus gemcitabine and cisplatin therapy followed by conversion surgery for initially unresectable advanced gallbladder cancer
Shuyuan Zhang, Jianhua Nie, Sheng Tai, et al.
BMJ Case Reports (2023) Vol. 16, Iss. 12, pp. e255403-e255403
Closed Access | Times Cited: 4
Shuyuan Zhang, Jianhua Nie, Sheng Tai, et al.
BMJ Case Reports (2023) Vol. 16, Iss. 12, pp. e255403-e255403
Closed Access | Times Cited: 4
Systematic sequential therapy for ex vivo liver resection and autotransplantation: A case report and review of literature
Chenlu Hu, Xin Han, Zhen-Zhen Gao, et al.
World Journal of Gastrointestinal Surgery (2023) Vol. 15, Iss. 11, pp. 2663-2673
Open Access | Times Cited: 2
Chenlu Hu, Xin Han, Zhen-Zhen Gao, et al.
World Journal of Gastrointestinal Surgery (2023) Vol. 15, Iss. 11, pp. 2663-2673
Open Access | Times Cited: 2
Conversion surgery after gemcitabine and cisplatin plus durvalumab for advanced intrahepatic cholangiocarcinoma: A case report
Yu Igata, Masashi Kudo, Motohiro Kojima, et al.
World Journal of Clinical Cases (2024) Vol. 12, Iss. 34, pp. 6721-6727
Closed Access
Yu Igata, Masashi Kudo, Motohiro Kojima, et al.
World Journal of Clinical Cases (2024) Vol. 12, Iss. 34, pp. 6721-6727
Closed Access
